Natera Promotes 15-Year Veteran Moshkevich to CEO as Chapman Steps Down
NTRA has more than doubled off its 52-week low of $181 on elevated volume (1.9× avg).
Summary
Natera named Solomon Moshkevich CEO and board member effective immediately, replacing Steve Chapman, who becomes a consultant and board advisor. This is an internal promotion, not a disruption: Moshkevich joined in 2011, ran the oncology business as its first general manager, and oversaw the commercial build-out of Panorama, Prospera and Signatera. Chapman's exit comes on the same day the company reported Q3 revenue of $794.0 million, up 34.1%, and raised full-year guidance — so the transition lands on a strong operating run-rate rather than amid weakness. The quarter's EPS was USD -0.42. The board, including executive chairman and co-founder Matthew Rabinowitz, is publicly backing the successor, which limits the read-through to strategy continuity in oncology and MRD. Watch the 4:30 p.m. ET earnings call for any commentary on the handoff and whether the raised guidance stands unchanged.
At the time of this announcement, NTRA was trading at $366.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.4B. The 52-week trading range was $181.00 to $437.41. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.